| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Immunology and Neurology (Drs. Villar, Masjuan, González-Porqué, Plaza, Roldán, and Bootello, and M. Sádaba), Hospital Ramón y Cajal, Madrid, Spain; and Department of Medicine (Dr. Alvarez-Cermeño), Alcalá de Henares University, Spain.
Address correspondence and reprint requests to Dr. Luisa María Villar, Servicio de Inmunología, Hospital Ramón y Cajal, Carretera de Colmenar Km 9.100, 28034 Madrid, Spain; e-mail: lvillar{at}hrc.insalud.es
Background: The authors have recently described that intrathecal IgM synthesis (ITMS) correlates with a higher disability in patients with clinically definite MS (CDMS).
Objective: To follow-up a group of patients with MS in the initial stages of the disease to evaluate if the presence of ITMS correlates with a worse evolution.
Methods: Oligoclonal IgM bands were performed in 22 patients with MS with a mean of 1.14 months of evolution. Patients were followed for a period ranging from 6 to 36 months (mean, 21.4 months). During follow-up, time to conversion to CDMS, number of relapses, and changes in Expanded Disability Status Scale (EDSS) score were evaluated.
Results: Patients were divided into two groups according to the presence (Group 1, 10 patients) or absence (Group 2, 12 patients) of ITMS. No clinical differences were observed between the groups at inclusion in the study. During the follow-up, the probability of conversion to CDMS was greater in Group 1 (90% of the patients had converted to CDMS after 8 months of follow-up) than in Group 2 (51% of patients had converted to CDMS after 36 months of follow-up) (p = 0.0001). Patients from Group 1 had more relapses (mean, 2.0) than those from Group 2 (mean, 0.58) (p = 0.02). At the end of the study, patients from Group 1 had higher EDSS scores (mean, 1.70) than those from Group 2 (mean, 0.79) (p = 0.02).
Conclusion: The presence of oligoclonal IgM bands in CSF can be a prognostic marker in the early phases of MS.
This article has been cited by other articles:
|
|
 |
|
  M Thangarajh, J Gomez-Rial, A. Hedstrom, J Hillert, J. Alvarez-Cermeno, T Masterman, and L. Villar Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis Multiple Sclerosis, November 1, 2008; 14(9): 1208 - 1213. [Abstract] [PDF]
|
|
|
|
|
|
L. Villar, N. Garcia-Barragan, M. Espino, E. Roldan, M. Sadaba, J. Gomez-Rial, P. Gonzalez-Porque, and J. Alvarez-Cermeno Influence of oligoclonal IgM specificity in multiple sclerosis disease course Multiple Sclerosis, March 1, 2008; 14(2): 183 - 187. [Abstract] [PDF]
|
|
|
|
 |
|
 P Perini, F Ranzato, M Calabrese, L Battistin, and P Gallo Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis J. Neurol. Neurosurg. Psychiatry, August 1, 2006; 77(8): 953 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Cepok, B. Rosche, V. Grummel, F. Vogel, D. Zhou, J. Sayn, N. Sommer, H.-P. Hartung, and B. Hemmer Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis Brain, July 1, 2005; 128(7): 1667 - 1676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Villar, J. Masjuan, M. C. Sadaba, P. Gonzalez-Porque, J. Plaza, A. Bootello, and J. C. Alvarez-Cermeno Early Differential Diagnosis of Multiple Sclerosis Using a New Oligoclonal Band Test Arch Neurol, April 1, 2005; 62(4): 574 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Pohl, K. Rostasy, H. Reiber, and F. Hanefeld CSF characteristics in early-onset multiple sclerosis Neurology, November 23, 2004; 63(10): 1966 - 1967. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
